Ampsource Biopharma Shanghai Inc.

Shandong New Time Pharmaceutical Co., Ltd.

Xinlu Ma

Qiang Li

Yuncheng Zheng

Yuanli Li

Lu Yang

Si Ruo Chen

Yongjuan Gao

Naichao Sun

Zirui Li

Zhu Wang

Zhao Dong

Tongtong Xue

Liang Xiao

Dengnian Liu

Guimin Zhang

Shixiang Jia

Yuhua Zhang

Lili Zhao

Zhenyu Li

Jiangjiang Hu

Jianyu Sun

Kangyong Zhu

Zhong Liu

Xingxia Hu

Bin Li

Yuan Yan

Yujie Yan

Yao Xiong

Yingying Jin

Rilong Sun

Xuemei Liu

Jiasheng Diao

Li Zhou

Xueyuan Cui

Lingju Yu

The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.

Bispecific antibody binding BCMA and CD3

Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Antibody against TIM-3 and application thereof

A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin &#x3b2;-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable.

Linker peptide for constructing fusion protein

This disclosure provides an antibody specifically binding to PD-1 with high affinity. Also provided are a nucleic acid molecule for coding the antibody, an expression vector and a host cell for expressing the antibody, and a production method for the antibody. In addition, also provided are an immunoconjugate and a pharmaceutical composition comprising the antibody and use of the antibody in preparation of drugs for treating cancers, infectious diseases, and inflammatory diseases.

Anti-PD-1 antibody and use thereof

Growing community of inventors

Shanghai, China

Xinlu Ma